Overview

A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Antibody-Associated Psychiatric Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2027-03-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ART5803 in adult participants with a confirmed diagnosis of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (ANRE) or anti-NMDAR antibody-associated psychiatric disease
Phase:
PHASE2
Details
Lead Sponsor:
Arialys Australia Pty Ltd